Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting

• Published in: Therapeutic advances in chronic disease Vol. 14; p. 20406223231213251
• Main Authors: Yin, Xuejiao, Liu, Yi, Sun, Jianai, Tong, Hongyan, Meng, Haitao, You, Liangshun
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2023; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Chronic illnesses; Immunotherapy; Multiple myeloma; bispecific antibody; multiple myeloma; immunotherapy
• ISSN: 2040-6223; 2040-6231
• DOI: 10.1177/20406223231213251

Background: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells. Objectives: Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a significant clinical challenge. Design: This is a brief report. Methods: This article summarizes the latest updates of BsAbs treatment of MM from the 2022 ASH annual meeting. Results: BsAbs that target B-cell maturation antigen and G protein-coupled receptor family C group 5 memberD have demonstrated remarkable clinical activity and favorable safety profiles. Many potential targets for myeloma cells are currently undergoing phase I/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape. Conclusion: This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the 2022 ASH annual meeting.